Entera Bio (ENTX) Price & Analysis

Compare

410 Followers

ENTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.50 - $2.79

Previous CloseN/A

Volume29.71K

Average Volume (3M)201.41K

Market Cap

$82.72M

Enterprise Value$70.32M

Total Cash (Recent Filing)$12.57M

Total Debt (Recent Filing)$220.00K

Price to Earnings (P/E)―

Beta0.89

Next Earnings

Nov 06, 2025

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding45,452,168

10 Day Avg. Volume526,920

30 Day Avg. Volume201,408

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.85

Enterprise Value/Revenue315.34

Enterprise Value/Gross Profit7.81K

Enterprise Value/Ebitda-9.39

Forecast

1Y Price Target

$10.00

Price Target Upside431.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Collaboration And LicensingEntera Bio and OPKO Health have entered into a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic disorders.

Funding And Financial SupportOPKO purchased roughly 3.7 million ordinary shares of Entera for $8 million, providing funding for Entera's share of the development costs.

Market OpportunityThe collaboration with OPKO provides access to a promising anti-obesity candidate, funding, and favorable economics in a large and lucrative market.

Bears Say

Clinical Development RisksRisks include failure to advance EB613 or EB612 through clinical development in a timely manner and inability to secure a partner to optimize the commercial value of EB613.

Financial PerformanceEntera reported a net loss per share mainly driven by higher than expected operating expenses.

Entera Bio News

Entera Bio receives FDA agreement on BMD as primary endpoint for EB613 study

Entera Bio (ENTX) announced that in a written response to a Type A meeting request, the U.S. Food...

15d ago

ENTX

Entera Bio’s Promising Phase 3 Study and Market Potential Drive Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Entera Bio, with a price target of...

23h ago

ENTX

Entera Bio Reports Q2 2025 Financial Results and Strategic Progress

Entera Bio ( ($ENTX) ) has released its Q2 earnings. Here is a breakdown of the information Entera...

3d ago

ENTX

Entera Bio Reports Q2 2025 Financial Results

Entera Bio ( ($ENTX) ) has issued an announcement. Entera Bio announced its second quarter 2025 financial results...

4d ago

ENTX

Entera Bio Advances EB613 with FDA Approval

The latest update is out from Entera Bio ( ($ENTX) ). On July 28, 2025, Entera Bio announced...

15d ago

ENTX

Entera Bio Elects New Board Member at Annual Meeting

Entera Bio ( ($ENTX) ) has provided an announcement. Entera Bio Ltd. held its 2025 Annual Meeting of...

25d ago

ENTX

Entera Bio announces data for EB613 to be presented at ASBMR 2025

Entera Bio (ENTX) announced that new data exploring the dual actions of EB613 on trabecular and cortical bone...

2M ago

ENTX

Entera Bio, Opko Health announce new in vivo data for OPK-88006

OPKO Health (OPK) and Entera Bio (ENTX) announced that new pharmacologic and pharmacokinetic in vivo data for investigational...

2M ago

OPK

ENTX

Opko Health, Entera Bio say OPK-88006 data selected for ENDO 2025

OPKO Health (OPK) and Entera Bio (ENTX) announced that new pharmacologic and pharmacokinetic in vivo data for investigational...

2M ago

OPK

ENTX

Entera Bio files $100M mixed securities shelf

16:07 EDT Entera Bio (ENTX) files $100M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

ENTX

Entera Bio Reports Q1 2025 Financial Results and Strategic Developments

Entera Bio ( ($ENTX) ) has released its Q1 earnings. Here is a breakdown of the information Entera...

3M ago

ENTX

Entera Bio Reports Q1 2025 Results and Strategic Updates

The latest announcement is out from Entera Bio ( ($ENTX) ). Entera Bio announced its first quarter 2025...

3M ago

ENTX

Entera Bio announces highlights from presentation at WCO-IFO-ESCEO on EB613

Entera Bio (ENTX) announced highlights from Dr. Rachel B Wagman’s oral presentation at the 2025 World Congress on...

4M ago

ENTX

Entera Bio Reports Transformative Year in 2024

Entera Bio ( ($ENTX) ) has released its Q4 earnings. Here is a breakdown of the information Entera...

5M ago

ENTX

ENTX FAQ

What was Entera Bio Ltd’s price range in the past 12 months?

Entera Bio Ltd lowest stock price was $1.50 and its highest was $2.79 in the past 12 months.

What is Entera Bio Ltd’s market cap?

Entera Bio Ltd’s market cap is $82.72M.

When is Entera Bio Ltd’s upcoming earnings report date?

Entera Bio Ltd’s upcoming earnings report date is Nov 06, 2025 which is in 86 days.

How were Entera Bio Ltd’s earnings last quarter?

Entera Bio Ltd released its earnings results on Aug 08, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.11 by $0.05.

Is Entera Bio Ltd overvalued?

According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Entera Bio Ltd pay dividends?

Entera Bio Ltd does not currently pay dividends.

What is Entera Bio Ltd’s EPS estimate?

Entera Bio Ltd’s EPS estimate is -0.09.

How many shares outstanding does Entera Bio Ltd have?

Entera Bio Ltd has 45,452,168 shares outstanding.

What happened to Entera Bio Ltd’s price movement after its last earnings report?

Entera Bio Ltd reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.11. Following the earnings report the stock price went up 3.297%.

Which hedge fund is a major shareholder of Entera Bio Ltd?

Currently, no hedge funds are holding shares in ENTX

Entera Bio Stock Smart Score

Underperform

Fundamentals

Return on Equity

-82.22%

Trailing 12-Months

Asset Growth

95.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Entera Bio Ltd

Entera Bio Ltd. is a biotechnology company engaged in the development of orally delivered large molecule therapeutics. The company primarily operates within the pharmaceutical and biotechnology sectors, focusing on the advancement of oral formulations of injectable drugs. Entera Bio's core products aim to address unmet medical needs in areas like osteoporosis and hypoparathyroidism by providing more convenient oral delivery options for patients.

Entera Bio (ENTX) Earnings & Revenues

Historic Earnings Reports

ENTX Stock 12 Month Forecast

Average Price Target

$10.00

▲(431.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.95,2.569230769230769,3.1884615384615387,3.8076923076923075,4.426923076923077,5.046153846153846,5.665384615384616,6.2846153846153845,6.903846153846154,7.523076923076924,8.142307692307693,8.76153846153846,9.38076923076923,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.95,2.569230769230769,3.1884615384615387,3.8076923076923075,4.426923076923077,5.046153846153846,5.665384615384616,6.2846153846153845,6.903846153846154,7.523076923076924,8.142307692307693,8.76153846153846,9.38076923076923,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.95,2.569230769230769,3.1884615384615387,3.8076923076923075,4.426923076923077,5.046153846153846,5.665384615384616,6.2846153846153845,6.903846153846154,7.523076923076924,8.142307692307693,8.76153846153846,9.38076923076923,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.66,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >